PharmaEssentia Corp (6446)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PharmaEssentia Corp (6446) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014000
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PharmaEssentia Corp (PharmaEssentia) is a research and development company that develops therapeutic products for the treatment of human diseases. The company’s pipeline product include P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the bloodstreamd. PharmaEssentia’s products can be used in the therapeutic areas of dermatology, hematology, infectious diseases, and oncology. The company also provides contract research and development, and clinical trial services. It collaborates with biotechnology companies, university research institutes, and pharmaceutical companies. PharmaEssentia is headquartered in Taipei, Taiwan.

PharmaEssentia Corp (6446) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
PharmaEssentia Amends its Licensing Agreement with Athenex for Oraxol and Oratecan 10
PharmaEssentia Amends its Licensing Agreement with Kinex Pharma 11
Equity Offering 13
PharmaEssentia Raises USD88 Million in Public Offering of Shares 13
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 14
PharmaEssentia Corp – Key Competitors 15
PharmaEssentia Corp – Key Employees 16
PharmaEssentia Corp – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Clinical Trials 18
Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016 18
Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation 20
Feb 22, 2016: PharmaEssentia Announces Phase II Results of P1101, an Innovative, Mono-pegylated Interferon in Patients with Chronic HCV Genotype 1 Infection 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
PharmaEssentia Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PharmaEssentia Corp, Deals By Therapy Area, 2011 to YTD 2017 8
PharmaEssentia Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
PharmaEssentia Amends its Licensing Agreement with Athenex for Oraxol and Oratecan 10
PharmaEssentia Amends its Licensing Agreement with Kinex Pharma 11
PharmaEssentia Raises USD88 Million in Public Offering of Shares 13
PharmaEssentia Raises USD20.5 Million in Rights Offering of Shares 14
PharmaEssentia Corp, Key Competitors 15
PharmaEssentia Corp, Key Employees 16
PharmaEssentia Corp, Other Locations 17

★海外企業調査レポート[PharmaEssentia Corp (6446)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Airbus SAS:企業のM&A・事業提携・投資動向
    Airbus SAS - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Airbus SAS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • CSG Systems International Inc (CSGS):企業の財務・戦略的SWOT分析
    CSG Systems International Inc (CSGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Exiqon AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Exiqon AS (Exiqon), a subsidiary of Qiagen NV, is a medical device company that develops, manufactures and markets molecular diagnostic test products. The company provides product categories such as microRNA research, incRNA research, mRNA research, DNA research, custom oligos and other reag …
  • Orig3N Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Orig3N Inc (Orig3N), a biotechnology company that focuses on the research, development and treatment of genetically inherited diseases. The company offers DNA test kits which include SUPERHERO for analyzing strength, intelligence and speed; FITNESS that provides reports and analysis on vario …
  • Ubiquiti Networks Inc:企業の戦略・SWOT・財務分析
    Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report Summary Ubiquiti Networks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Abeona Therapeutics Inc (ABEO):企業の財務・戦略的SWOT分析
    Abeona Therapeutics Inc (ABEO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ashok Leyland Ltd (ASHOKLEY):企業の財務・戦略的SWOT分析
    Ashok Leyland Ltd (ASHOKLEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Otsuka Corp (4768):企業の財務・戦略的SWOT分析
    Otsuka Corp (4768) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bionik Laboratories Corp (BNKL):企業の財務・戦略的SWOT分析
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company offers rehabilitation technology that senses patient movements and limitations. It provides lower body e …
  • Curetis NV (CURE):企業の製品パイプライン分析2018
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • Independent Electricity System Operator:企業の戦略的SWOT分析
    Independent Electricity System Operator - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Aegion Corp (AEGN):企業の財務・戦略的SWOT分析
    Aegion Corp (AEGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Applus Services, S.A.:企業のM&A・事業提携・投資動向
    Applus Services, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Applus Services, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Bta Bank Jsc:企業の戦略・SWOT・財務分析
    Bta Bank Jsc - Strategy, SWOT and Corporate Finance Report Summary Bta Bank Jsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Seacoast Banking Corporation of Florida:企業の戦略・SWOT・財務情報
    Seacoast Banking Corporation of Florida - Strategy, SWOT and Corporate Finance Report Summary Seacoast Banking Corporation of Florida - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Nano-Terra Inc-製薬・医療分野:企業M&A・提携分析
    Summary Nano-Terra Inc (Nano-Terra) is a clean technology company that develops and commercializes nano technology products. The company’s products include coating, advanced materials, organic and inorganic molecules, materials, polymers and UV water filtration system. It provides surface science, c …
  • Eesti Energia AS:企業の戦略・SWOT・財務情報
    Eesti Energia AS - Strategy, SWOT and Corporate Finance Report Summary Eesti Energia AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • UroGen Pharma Ltd (URGN)-製薬・医療分野:企業M&A・提携分析
    Summary UroGen Pharma Ltd (UroGen Pharma), formerly TheraCoat Ltd is a biopharmaceutical company that develops uro-oncology drugs and urological pathologies. The company’s pipeline products comprise drug candidates for various forms of non-muscle invasive urothelial cancer, including low grade bladd …
  • CTCI Corporation (9933)-エネルギー分野:企業M&A・提携分析
    Summary CTCI Corporation (CTCI) is an engineering, procurement, and construction services provider that operates along with its subsidiaries and affiliates. It offers construction services includes feasibility study, design, and fabrication; project related services: project management, supervision, …
  • Fuwei Films Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Fuwei Films Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Fuwei Films Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆